

Philippe L Bedard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5636220/publications.pdf>

Version: 2024-02-01

194
papers

11,049
citations

38720

50
h-index

34964

98
g-index

195
all docs

195
docs citations

195
times ranked

18470
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Tumour heterogeneity in the clinic. <i>Nature</i> , 2013, 501, 355-364. | 13.7 | 993 |
| 2 | Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 597-609. | 13.9 | 789 |
| 3 | Sensitive tumour detection and classification using plasma cell-free DNA methylomes. <i>Nature</i> , 2018, 563, 579-583. | 13.7 | 624 |
| 4 | Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling. <i>Clinical Cancer Research</i> , 2012, 18, 1341-1351. | 3.2 | 303 |
| 5 | Small molecules, big impact: 20 years of targeted therapy in oncology. <i>Lancet, The</i> , 2020, 395, 1078-1088. | 6.3 | 302 |
| 6 | The Genetic Basis for Cancer Treatment Decisions. <i>Cell</i> , 2012, 148, 409-420. | 13.5 | 299 |
| 7 | Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt319-djt319. | 3.0 | 279 |
| 8 | Patterns of Relapse in Patients With Clinical Stage I Testicular Cancer Managed With Active Surveillance. <i>Journal of Clinical Oncology</i> , 2015, 33, 51-57. | 0.8 | 268 |
| 9 | A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 730-738. | 3.2 | 265 |
| 10 | Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. <i>Nature Cancer</i> , 2020, 1, 873-881. | 5.7 | 253 |
| 11 | Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2804-2811. | 3.2 | 249 |
| 12 | AKT Inhibition in Solid Tumors With <i>AKT1</i> Mutations. <i>Journal of Clinical Oncology</i> , 2017, 35, 2251-2259. | 0.8 | 240 |
| 13 | Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , 2016, 8, 109. | 3.6 | 211 |
| 14 | International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1174-1181. | 3.0 | 202 |
| 15 | Luminal-B breast cancer and novel therapeutic targets. <i>Breast Cancer Research</i> , 2011, 13, 221. | 2.2 | 185 |
| 16 | A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. <i>Annals of Oncology</i> , 2015, 26, 1824-1829. | 0.6 | 184 |
| 17 | Cancer Genomics: Technology, Discovery, and Translation. <i>Journal of Clinical Oncology</i> , 2012, 30, 647-660. | 0.8 | 173 |
| 18 | Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5687-5695. | 3.2 | 170 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spatalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 3620-3629. | 3.2 | 151 |
| 20 | A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in Patients With Advanced Solid Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 484-490. | 0.6 | 141 |
| 21 | A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 1100-1107. | 1.2 | 121 |
| 22 | Ocular Toxicity of Targeted Therapies. <i>Journal of Clinical Oncology</i> , 2012, 30, 3277-3286. | 0.8 | 117 |
| 23 | Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities. <i>Cancer</i> , 2019, 125, 1341-1349. | 2.0 | 115 |
| 24 | Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor. <i>Journal of Urology</i> , 2018, 200, 126-135. | 0.2 | 107 |
| 25 | Disease modification and biomarker development in Parkinson disease. <i>Neurology</i> , 2020, 94, 481-494. | 1.5 | 103 |
| 26 | Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care. <i>European Journal of Human Genetics</i> , 2014, 22, 391-395. | 1.4 | 98 |
| 27 | Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 22-36. | 12.5 | 97 |
| 28 | A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 2050-2059. | 3.2 | 96 |
| 29 | Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?. <i>Targeted Oncology</i> , 2009, 4, 77-88. | 1.7 | 90 |
| 30 | Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?. <i>Cancer Research</i> , 2014, 74, 4016-4023. | 0.4 | 90 |
| 31 | Promising SINEs for Embargoing Nuclear Cytoplasmic Export as an Anticancer Strategy. <i>Cancer Discovery</i> , 2014, 4, 527-537. | 7.7 | 89 |
| 32 | Evolution of Clinical Trial Design in Early Drug Development: Systematic Review of Expansion Cohort Use in Single-Agent Phase I Cancer Trials. <i>Journal of Clinical Oncology</i> , 2013, 31, 4260-4267. | 0.8 | 83 |
| 33 | A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. <i>Genetics in Medicine</i> , 2016, 18, 128-136. | 1.1 | 83 |
| 34 | Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811. | 7.7 | 79 |
| 35 | Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial. <i>International Journal of Cancer</i> , 2013, 132, 1547-1555. | 2.3 | 76 |
| 36 | Genomic testing in cancer: Patient knowledge, attitudes, and expectations. <i>Cancer</i> , 2014, 120, 3066-3073. | 2.0 | 72 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Ocular toxicities of MEK inhibitors and other targeted therapies. <i>Annals of Oncology</i> , 2016, 27, 998-1005. | 0.6 | 72 |
| 38 | Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv362. | 3.0 | 71 |
| 39 | A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). <i>Investigational New Drugs</i> , 2014, 32, 243-249. | 1.2 | 70 |
| 40 | A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2016, 34, 740-749. | 1.2 | 67 |
| 41 | Testicular cancer survivors' supportive care needs and use of online support: a cross-sectional survey. <i>Supportive Care in Cancer</i> , 2012, 20, 2737-2746. | 1.0 | 65 |
| 42 | A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503). <i>British Journal of Cancer</i> , 2013, 109, 943-949. | 2.9 | 65 |
| 43 | Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario. <i>Journal of Clinical Oncology</i> , 2016, 34, 1065-1071. | 0.8 | 65 |
| 44 | Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. <i>British Journal of Cancer</i> , 2010, 103, 1788-1793. | 2.9 | 64 |
| 45 | A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. <i>Lancet Oncology</i> , The, 2012, 13, e240-e248. | 5.1 | 64 |
| 46 | Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. <i>Nature Communications</i> , 2021, 12, 5137. | 5.8 | 63 |
| 47 | Statistical Power of Negative Randomized Controlled Trials Presented at American Society for Clinical Oncology Annual Meetings. <i>Journal of Clinical Oncology</i> , 2007, 25, 3482-3487. | 0.8 | 61 |
| 48 | Stemming Resistance to HER-2 Targeted Therapy. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2009, 14, 55-66. | 1.0 | 57 |
| 49 | Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with <i>RAS/RAF</i> Alterations. <i>Oncologist</i> , 2020, 25, e160-e169. | 1.9 | 55 |
| 50 | Identification of genomic signatures in circulating tumor cells from breast cancer. <i>International Journal of Cancer</i> , 2015, 137, 332-344. | 2.3 | 54 |
| 51 | Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer. <i>European Urology</i> , 2017, 71, 120-127. | 0.9 | 54 |
| 52 | Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer. <i>Current Cancer Drug Targets</i> , 2009, 9, 148-162. | 0.8 | 53 |
| 53 | OncoTree: A Cancer Classification System for Precision Oncology. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 221-230. | 1.0 | 51 |
| 54 | A phase Ib combination study of R04929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 1182-1191. | 1.2 | 50 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Large Retroperitoneal Lymphadenopathy As a Predictor of Venous Thromboembolism in Patients With Disseminated Germ Cell Tumors Treated With Chemotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 582-587. | 0.8 | 50 |
| 56 | Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4380-4387. | 3.2 | 49 |
| 57 | A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 1348-1355. | 3.2 | 48 |
| 58 | Author Financial Conflicts of Interest, Industry Funding, and Clinical Practice Guidelines for Anticancer Drugs. <i>Journal of Clinical Oncology</i> , 2015, 33, 100-106. | 0.8 | 47 |
| 59 | Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance. <i>Journal of Clinical Oncology</i> , 2019, 37, 1919-1926. | 0.8 | 47 |
| 60 | The positive effect of a dedicated adolescent and young adult fertility program on the rates of documentation of therapy-associated infertility risk and fertility preservation options. <i>Supportive Care in Cancer</i> , 2017, 25, 1915-1922. | 1.0 | 46 |
| 61 | A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. <i>Investigational New Drugs</i> , 2014, 32, 1269-1277. | 1.2 | 45 |
| 62 | Right Ventricular Dysfunction in Patients Experiencing Cardiotoxicity during Breast Cancer Therapy. <i>Journal of Oncology</i> , 2015, 2015, 1-10. | 0.6 | 43 |
| 63 | Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies. <i>Nature Communications</i> , 2022, 13, . | 5.8 | 43 |
| 64 | Overcoming endocrine resistance in breast cancer—are signal transduction inhibitors the answer?. <i>Breast Cancer Research and Treatment</i> , 2008, 108, 307-317. | 1.1 | 41 |
| 65 | Association Between <i>SLC16A5</i> Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer. <i>JAMA Oncology</i> , 2017, 3, 1558. | 3.4 | 41 |
| 66 | Lucitanib for the Treatment of HR+/HER2 ⁺ Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. <i>Clinical Cancer Research</i> , 2020, 26, 354-363. | 3.2 | 40 |
| 67 | Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer. <i>European Urology Oncology</i> , 2021, 4, 483-491. | 2.6 | 39 |
| 68 | Brain metastases in HER2-positive breast cancer: The evolving role of lapatinib. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 75, 110-121. | 2.0 | 38 |
| 69 | An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)., 2019, 7, 72. | | 38 |
| 70 | Cost-Effectiveness of the 21-Gene Assay for Guiding Adjuvant Chemotherapy Decisions in Early Breast Cancer. <i>Value in Health</i> , 2013, 16, 729-739. | 0.1 | 36 |
| 71 | Somatic Tumor Variant Filtration Strategies to Optimize Tumor-Only Molecular Profiling Using Targeted Next-Generation Sequencing Panels. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 261-273. | 1.2 | 36 |
| 72 | An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors. , 2020, 8, e000883. | | 36 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Characteristics and Outcome of <i>AKT1</i> -E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry. <i>Cancer Discovery</i> , 2020, 10, 526-535. | 7.7 | 36 |
| 74 | Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial. <i>British Journal of Cancer</i> , 2019, 121, 318-324. | 2.9 | 35 |
| 75 | A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies. <i>British Journal of Cancer</i> , 2015, 112, 650-659. | 2.9 | 34 |
| 76 | American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond—Lessons Learned and Member Institutions' Perspectives. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-14. | 1.0 | 33 |
| 77 | Quality of life and understanding of disease status among cancer patients of different ethnic origin. <i>British Journal of Cancer</i> , 2003, 89, 641-647. | 2.9 | 32 |
| 78 | The Future of Clinical Trial Design in Oncology. <i>Cancer Discovery</i> , 2021, 11, 822-837. | 7.7 | 32 |
| 79 | Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy. <i>Journal of Clinical Oncology</i> , 2016, 34, 714-720. | 0.8 | 31 |
| 80 | Current Paradigms for the Use of HER2-Targeted Therapy in Early-Stage Breast Cancer. <i>Clinical Breast Cancer</i> , 2008, 8, S157-S165. | 1.1 | 30 |
| 81 | First-in-human trial of the PI3K β -selective inhibitor SAR260301 in patients with advanced solid tumors. <i>Cancer</i> , 2018, 124, 315-324. | 2.0 | 29 |
| 82 | <i>TP53</i> mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 346-352. | 1.2 | 29 |
| 83 | Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 272-279. | 12.5 | 28 |
| 84 | Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC). <i>Gynecologic Oncology</i> , 2017, 144, 250-255. | 0.6 | 27 |
| 85 | Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 159-168. | 1.1 | 27 |
| 86 | A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma. <i>European Urology Focus</i> , 2018, 4, 995-1001. | 1.6 | 26 |
| 87 | Development of the Functional Assessment of Cancer Therapy—Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. <i>Cancer</i> , 2020, 126, 1550-1558. | 2.0 | 26 |
| 88 | Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?. <i>BMC Cancer</i> , 2011, 11, 426. | 1.1 | 25 |
| 89 | Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2021, 113, 980-988. | 3.0 | 25 |
| 90 | The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32. <i>Journal of the National Cancer Institute</i> , 2021, 113, 192-198. | 3.0 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Lymph Node Yield in Primary Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumors. <i>Journal of Urology</i> , 2015, 194, 386-391. | 0.2 | 23 |
| 92 | Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library. <i>Oncologist</i> , 2019, 24, e146-e148. | 1.9 | 23 |
| 93 | Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers. <i>Clinical Cancer Research</i> , 2021, 27, 447-459. | 3.2 | 22 |
| 94 | Applying Radiomics to Predict Pathology of Postchemotherapy Retroperitoneal Nodal Masses in Germ Cell Tumors. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-12. | 1.0 | 21 |
| 95 | Outcome Definition Influences the Relationship between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients. <i>Genes</i> , 2019, 10, 364. | 1.0 | 21 |
| 96 | Cancer patients' experiences with immune checkpoint modulators: A qualitative study. <i>Cancer Medicine</i> , 2020, 9, 3015-3022. | 1.3 | 21 |
| 97 | A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 520-520. | 0.8 | 21 |
| 98 | Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2117547. | 2.8 | 20 |
| 99 | Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. <i>Lancet Oncology</i> , The, 2011, 12, 1162-1168. | 5.1 | 17 |
| 100 | Clinical application of high-throughput genomic technologies for treatment selection in breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R97. | 2.2 | 17 |
| 101 | A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCT019041). <i>Investigational New Drugs</i> , 2016, 34, 104-111. | 1.2 | 17 |
| 102 | Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. <i>Clinical Colorectal Cancer</i> , 2018, 17, 73-79. | 1.0 | 17 |
| 103 | Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3). <i>Cancer Medicine</i> , 2020, 9, 116-124. | 1.3 | 17 |
| 104 | A phase Ib, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3003-3003. | 0.8 | 17 |
| 105 | Low CD10 mRNA Expression Identifies High-Risk Ductal Carcinoma In Situ (DCIS). <i>PLoS ONE</i> , 2010, 5, e12100. | 1.1 | 16 |
| 106 | Additional germline findings from a tumor profiling program. <i>BMC Medical Genomics</i> , 2018, 11, 65. | 0.7 | 16 |
| 107 | Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS).. <i>Journal of Clinical Oncology</i> , 2013, 31, 11002-11002. | 0.8 | 16 |
| 108 | Therapeutic management of breast cancer in the elderly. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 945-960. | 0.9 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Modifying phase I methodology to facilitate enrolment of molecularly selected patients. <i>European Journal of Cancer</i> , 2013, 49, 1515-1520. | 1.3 | 15 |
| 110 | Long-Term Mental Health Service Utilization Among Survivors of Testicular Cancer: A Population-Based Cohort Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 779-786. | 0.8 | 15 |
| 111 | A phase III trial of alpelisib+trastuzumab ±fulvestrant versus trastuzumab+ chemotherapy in HER2+ <i>PIK3CA</i>-mutated breast cancer. <i>Future Oncology</i> , 2022, 18, 2339-2349. | 1.1 | 15 |
| 112 | Management of small HER2 overexpressing tumours. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 289-293. | 1.1 | 14 |
| 113 | Clinical genomics information management software linking cancer genome sequence and clinical decisions. <i>Genomics</i> , 2013, 102, 140-147. | 1.3 | 14 |
| 114 | <i>PIK3CA</i> Genotype and Treatment Decisions in Human Epidermal Growth Factor Receptor 2+ Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1318-1321. | 0.8 | 14 |
| 115 | Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa115. | 1.4 | 14 |
| 116 | Benefits and Harms of Detecting Clinically Occult Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1542-1547. | 3.0 | 13 |
| 117 | Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e193-e199. | 0.9 | 13 |
| 118 | A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy. <i>European Urology Focus</i> , 2021, 7, 1130-1136. | 1.6 | 13 |
| 119 | Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor. <i>European Urology Oncology</i> , 2021, 4, 289-296. | 2.6 | 13 |
| 120 | Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2^{mut} MBC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 516-516. | 0.8 | 13 |
| 121 | Sowing the Soil for Cure? Results of the ABCSG-12 Trial Open a New Chapter in the Evolving Adjuvant Bisphosphonate Story in Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4043-4046. | 0.8 | 12 |
| 122 | Recommendations for followup of stage I and II seminoma: The Princess Margaret Cancer Centre approach. <i>Canadian Urological Association Journal</i> , 2017, 12, 59-66. | 0.3 | 12 |
| 123 | Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa122. | 1.4 | 12 |
| 124 | Detection of Relapse by Low-dose Computed Tomography During Surveillance in Stage I Testicular Germ Cell Tumours. <i>European Urology Oncology</i> , 2019, 2, 437-442. | 2.6 | 11 |
| 125 | Pharmacokinetics and Safety of PTC596, a Novel Tubulin-Binding Agent, in Subjects With Advanced Solid Tumors. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 940-949. | 0.8 | 11 |
| 126 | Tilting the Balance of Dose Modification for Oral Anticancer Drugs?. <i>Journal of Clinical Oncology</i> , 2014, 32, 1537-1539. | 0.8 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | The association between institution at orchiectomy and outcomes on active surveillance for clinical stage I germ cell tumours. Canadian Urological Association Journal, 2016, 10, 204. | 0.3 | 10 |
| 128 | A Matched Cohort Study of Patients With End-Stage Heart Failure from Anthracycline-Induced Cardiomyopathy Requiring Advanced Cardiac Support. American Journal of Cardiology, 2016, 118, 1539-1544. | 0.7 | 10 |
| 129 | Fertility preservation in post-pubescent female cancer patients: A practical guideline for clinicians. Molecular and Clinical Oncology, 2017, 8, 153-158. | 0.4 | 10 |
| 130 | The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer. Current Oncology, 2021, 28, 107-114. | 0.9 | 10 |
| 131 | Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors. , 2022, 10, e003569. | | 10 |
| 132 | Are we HER-ting for innovation in neoadjuvant breast cancer trial design?. Breast Cancer Research, 2009, 11, 201. | 2.2 | 9 |
| 133 | MammaPrint 70-gene profile quantifies the likelihood of recurrence for early breast cancer. Expert Opinion on Medical Diagnostics, 2009, 3, 193-205. | 1.6 | 9 |
| 134 | Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications. Investigational New Drugs, 2017, 35, 827-833. | 1.2 | 9 |
| 135 | OCTANE (Ontario-Wide Cancer Targeted Nucleic Acid Evaluation): A Platform for Intraprovincial, National, and International Clinical Data-Sharing. Current Oncology, 2019, 26, 618-623. | 0.9 | 9 |
| 136 | Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2021, 20, 334-341. | 1.0 | 9 |
| 137 | Stage II Seminomas and Nonseminomas. Hematology/Oncology Clinics of North America, 2011, 25, 529-541. | 0.9 | 8 |
| 138 | Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer. Endocrine-Related Cancer, 2011, 18, 721-730. | 1.6 | 8 |
| 139 | Gene expression signatures prognostic for relapse in stage I testicular germ cell tumours. BJU International, 2018, 122, 814-822. | 1.3 | 8 |
| 140 | Novel classes of immunotherapy for breast cancer. Breast Cancer Research and Treatment, 2022, 191, 15-29. | 1.1 | 8 |
| 141 | Immune checkpoint inhibitor-related myocarditis: an illustrative case series of applying the updated Cardiovascular Magnetic Resonance Lake Louise Criteria. European Heart Journal - Case Reports, 2022, 6, ytab478. | 0.3 | 8 |
| 142 | Personalized medicine for metastatic breast cancer. Current Opinion in Oncology, 2013, 25, 615-624. | 1.1 | 6 |
| 143 | Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer. Journal of Clinical Pathology, 2015, 68, 839-843. | 1.0 | 6 |
| 144 | Standard and Genomic Tools for Decision Support in Breast Cancer Treatment. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 106-115. | 1.8 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Latency and interval therapy affect the evolution in metastatic colorectal cancer. <i>Scientific Reports</i> , 2020, 10, 581. | 1.6 | 6 |
| 146 | A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2500-2500. | 0.8 | 6 |
| 147 | Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry. <i>F1000Research</i> , 2020, 9, 337. | 0.8 | 6 |
| 148 | Safety of Minimizing Intensity of Follow-up on Active Surveillance for Clinical Stage I Testicular Germ Cell Tumors. <i>European Urology Open Science</i> , 2022, 40, 46-53. | 0.2 | 6 |
| 149 | The role of capecitabine in the management of breast cancer in elderly patients. <i>Journal of Geriatric Oncology</i> , 2011, 2, 72-81. | 0.5 | 5 |
| 150 | Testing <i>ERBB2</i> p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a001016. | 0.5 | 5 |
| 151 | Pathologic concordance of resected metastatic nonseminomatous germ cell tumors in the chest. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 161, 856-868.e1. | 0.4 | 5 |
| 152 | Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single-agent pembrolizumab (P).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2542-2542. | 0.8 | 5 |
| 153 | Heterogeneity of Circulating Tumor Cell-associated Genomic Gains in Breast Cancer and Its Association with the Host Immune Response. <i>Cancer Research</i> , 2021, 81, 6196-6206. | 0.4 | 5 |
| 154 | A Scalable Quality Assurance Process for Curating Oncology Electronic Health Records: The Project GENIE Biopharma Collaborative Approach. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100105. | 1.0 | 5 |
| 155 | No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer. <i>British Journal of Cancer</i> , 2022, 126, 881-888. | 2.9 | 5 |
| 156 | Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer. <i>Current Opinion in Oncology</i> , 2009, 21, 491-498. | 1.1 | 4 |
| 157 | Spinal cord stimulators and radiotherapy: First case report and practice guidelines. <i>Radiation Oncology</i> , 2011, 6, 143. | 1.2 | 4 |
| 158 | A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 121-133. | 1.1 | 4 |
| 159 | Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz071. | 1.4 | 4 |
| 160 | Controversies in the management of clinical stage 1 testis cancer. <i>Canadian Urological Association Journal</i> , 2020, 14, E537-E542. | 0.3 | 4 |
| 161 | Utilization of imaging for active surveillance in testicular cancer: Is real-world practice concordant with guidelines?. <i>Canadian Urological Association Journal</i> , 2021, 16, . | 0.3 | 4 |
| 162 | Semen and serum platinum levels in cisplatin-treated survivors of germ cell cancer. <i>Cancer Medicine</i> , 2022, 11, 728-734. | 1.3 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab. , 2022, 10, e004378. | | 4 |
| 164 | Aiming at the target: improved adjuvant medical therapy. Breast, 2009, 18, S25-S30. | 0.9 | 3 |
| 165 | Molecular Biology of Breast Cancer. , 2010, , 341-349. | | 3 |
| 166 | Anterior transpericardial approach for postchemotherapy residual midvisceral mediastinal mass in metastatic germ cell tumors. Journal of Thoracic and Cardiovascular Surgery, 2013, 145, 1136-1138. | 0.4 | 3 |
| 167 | Delivery of chemotherapy for testicular cancer in routine practice: A population-based study. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 183.e17-183.e24. | 0.8 | 3 |
| 168 | Abstract PD1-02: A phase I/Ib study evaluating GDC-0077 + palbociclib (palbo) + fulvestrant in patients (pts) with <i>PIK3CA</i> -mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC). Cancer Research, 2021, 81, PD1-02-PD1-02. | 0.4 | 3 |
| 169 | A phase I study of R04929097, an oral gamma secretase inhibitor, in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).. Journal of Clinical Oncology, 2012, 30, 3082-3082. | 0.8 | 3 |
| 170 | Natural History and Characteristics of <i>ERBB2</i> -mutated Hormone Receptor-“positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE. Clinical Cancer Research, 2022, 28, 2118-2130. | 3.2 | 3 |
| 171 | A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study. Targeted Oncology, 2022, 17, 271-281. | 1.7 | 3 |
| 172 | Nonhormonal Systemic Therapy for Advanced Breast Cancer: Do the Math!. Journal of the National Cancer Institute, 2008, 100, 1745-1747. | 3.0 | 2 |
| 173 | Decoding the evolution of a breast cancer genome. EMBO Molecular Medicine, 2010, 2, 3-5. | 3.3 | 2 |
| 174 | Elucidating the genomic landscape of breast cancer: how will this affect treatment?. Pharmacogenomics, 2015, 16, 569-572. | 0.6 | 2 |
| 175 | Beta-Testing of Next-Generation DNA Sequencing for Patients With Advanced Cancers Treated at Community Hospitals. Journal of Oncology Practice, 2016, 12, 279-281. | 2.5 | 2 |
| 176 | Incidental germline findings identified in a somatic genomic sequencing program for advanced cancer patients.. Journal of Clinical Oncology, 2016, 34, 1532-1532. | 0.8 | 2 |
| 177 | Abstract CT503: A phase I/Ib study of the safety and preliminary efficacy of NZV930 alone and in combination with spartalizumab and/or taminadenant in patients (pts) with advanced malignancies. Cancer Research, 2022, 82, CT503-CT503. | 0.4 | 2 |
| 178 | Molecular Biology of Breast Cancer. , 2009, , 501-517. | | 1 |
| 179 | MP10-10 OUTCOMES OF PROGRESSION ON SURVEILLANCE FOR CLINICAL STAGE I NONSEMINOMATOUS GERM CELL TUMOURS. Journal of Urology, 2015, 193, . | 0.2 | 1 |
| 180 | Randomized controlled trials in testicular cancer: A demographic and quality assessment. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 60.e7-60.e13. | 0.8 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer. <i>Future Oncology</i> , 2017, 13, 2733-2736. | 1.1 | 1 |
| 182 | Shrinking Hepatic Hemangiomas in a Patient Treated for Metastatic Germ Cell Tumor. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e69-e72. | 0.9 | 1 |
| 183 | Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era. <i>Oncologist</i> , 2019, 24, e518-e525. | 1.9 | 1 |
| 184 | Clinical dilemmas in local and regional testis cancer. <i>Canadian Urological Association Journal</i> , 2020, 15, E58-E64. | 0.3 | 1 |
| 185 | Abstract 4647: Tie2-expressing monocytes (TEMs) as potential biomarkers of angiopoietin-Tie2 (Ang/Tie2) directed therapies: correlative analysis of a phase I study of AMG386 + temsirolimus (T).., 2013, , . | | 1 |
| 186 | Doubling back on centromere 17 in early breast cancer. <i>Lancet Oncology</i> , The, 2010, 11, 216-217. | 5.1 | 0 |
| 187 | Response: Re: International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2010, 102, 207-208. | 3.0 | 0 |
| 188 | Minimally Invasive Real-Time Detection of Actionable Mutations in Patients With Metastatic Solid Tumors Using Fine-Needle and Liquid Biopsies. <i>JCO Precision Oncology</i> , 2018, 2, 1-20. | 1.5 | 0 |
| 189 | A Canadian approach to the regionalization of testis cancer: A review. <i>Canadian Urological Association Journal</i> , 2020, 14, 346-351. | 0.3 | 0 |
| 190 | Impact of renal impairment and granulocyte colony stimulating factor (GCSF) on bleomycin-induced pneumonitis (bleo lung), febrile neutropenia (FN), and survival in patients (pts) with germ cell tumor (GCT) treated with chemotherapy (chemo).. <i>Journal of Clinical Oncology</i> , 2012, 30, 328-328. | 0.8 | 0 |
| 191 | Large retroperitoneal lymph nodes (RPLN) as a novel risk factor for venous thromboembolism (VTE) in germ cell tumor (GCT) patients (pts) receiving first-line chemotherapy (chemo).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4535-4535. | 0.8 | 0 |
| 192 | <i>IDH</i>-1/2 mutations and associated oncometabolite 2-hydroxyglutarate (2-HG) in solid tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23210-e23210. | 0.8 | 0 |
| 193 | P53 functional mutation type in high-grade serous ovarian cancer and clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5550-5550. | 0.8 | 0 |
| 194 | Comparison of genotype-specific progression free survival (PFS) outcomes in the control (ctrl) arms of randomized clinical trials (RCTs).. <i>Journal of Clinical Oncology</i> , 2016, 34, 2536-2536. | 0.8 | 0 |